ReviewMolecular biology reports2026
The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chaperonin Containing TCP1 Subunit 6A (CCT6A), a structurally conserved core subunit of the eukaryotic CCT/TRiC complex, orchestrates ATP-dependent protein folding, cytoskeletal dynamics, and stress-responsive adaptation, reflecting its indispensable role in cellular homeostasis. Emerging evidence highlights CCT6A as a multifaceted oncogenic driver across diverse malignancies (such as colorectal cancer and hepatocellular carcinoma), through metabolic reprogramming, stabilization of oncoproteins, and immunosuppression. Its overexpression correlates with aggressive phenotypes, therapeutic resistance, and poor prognosis, positioning it as a robust diagnostic and prognostic biomarker. Beyond oncology, CCT6A also contributes to autoimmune diseases, pulmonary fibrosis, and acute kidney injury. Despite its therapeutic potential, key challenges include unresolved context-dependent signaling mechanisms, absence of subunit-specific inhibitors, and the need to reconcile CCT6A targeting with preservation of CCT complex functionality. This review delineates CCT6A's multifunctional roles in oncogenesis and immune-metabolic dysregulation, critically evaluates its biomarker potential, and proposes targeted therapeutic frameworks to refine precision medicine paradigms across diverse disease landscapes.
Indexed as
Identifiers
42758405What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.